journal article·2021-06Open access

Graphene Oxide Nanosheets Interact and Interfere with SARS‐CoV‐2 Surface Proteins and Cell Receptors to Inhibit Infectivity

Mehmet Altay Unal, Fatma Bayrakdar, Hasan Nazir, Omur Besbinar, Cansu Gurcan, Neus Lozano, Luis M. Arellano, Süleyman Yalcin, Oguzhan Panatli, Dogantan Celik, Damla Alkaya, Aydan Agan, Laura Fusco, Serap Suzuk Yildiz, Lucia Gemma Delogu, Kamil Can Akcali, Kostas Kostarelos, Açelya Yilmazer

Small· Volume 17· Issue 25

Abstract

Abstract Nanotechnology can offer a number of options against coronavirus disease 2019 (COVID‐19) acting both extracellularly and intracellularly to the host cells. Here, the aim is to explore graphene oxide (GO), the most studied 2D nanomaterial in biomedical applications, as a nanoscale platform for interaction with SARS‐CoV‐2. Molecular docking analyses of GO sheets on interaction with three different structures: SARS‐CoV‐2 viral spike (open state – 6VYB or closed state – 6VXX), ACE2 (1R42), and the ACE2‐bound spike complex (6M0J) are performed. GO shows high affinity for the surface of all three structures (6M0J, 6VYB and 6VXX). When binding affinities and involved bonding types are compared, GO interacts more strongly with the spike or ACE2, compared to 6M0J. Infection experiments using infectious viral particles from four different clades as classified by Global Initiative on Sharing all Influenza Data (GISAID), are performed for validation purposes. Thin, biological‐grade GO nanoscale (few hundred nanometers in lateral dimension) sheets are able to significantly reduce copies for three different viral clades. This data has demonstrated that GO sheets have the capacity to interact with SARS‐CoV‐2 surface components and disrupt infectivity even in the presence of any mutations on the viral spike. GO nanosheets are proposed to be further explored as a nanoscale platform for development of antiviral strategies against COVID‐19.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Graphene and Nanomaterials Applications · COVID-19 Clinical Research Studies · SARS-CoV-2 detection and testing

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Stem Cell Institute Ankara University Balgat Ankara 06520 Turkey

Ministry of Health General Directorate of Public Health Microbiology References Laboratory Sihhiye Ankara 06430 Turkey

Department of Chemistry Ankara University Tandogan Ankara 06100 Turkey

Department of Biomedical Engineering Ankara University Golbasi Ankara 06830 Turkey

Catalan Institute of Nanoscience and Nanotechnology (ICN2) UAB Campus Bellaterra Barcelona 08193 Spain

Department of Biomedical Sciences University of Padua Padua 35122 Italy

Department of Biophysics Faculty of Medicine Ankara University Sihhiye Ankara 06230 Turkey

Nanomedicine Lab National Graphene Institute and Faculty of Biology Medicine & Health The University of Manchester AV Hill Building Manchester M13 9PT United Kingdom

Funding

Türkiye Bilimler Akademisi · Türkiye Bilimsel ve Teknolojik Araştirma Kurumu · Engineering and Physical Sciences Research Council

References (88)

Show source-provided references
1. COVID‐19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU) https://coronavirus.jhu.edu/map.html(accessed: April 2021).
2. Shanmugaraj B. · Asian Pac. J. Allergy Immunol. · 2020 · 1 · 10
3. 10.3390/ijms2107265710.3390/ijms21072657 ↗
4. 10.1021/acsnano.0c0369710.1021/acsnano.0c03697 ↗
5. 10.1038/s41586-020-2577-110.1038/s41586-020-2577-1 ↗
6. 10.1038/d41587-020-00003-110.1038/d41587-020-00003-1 ↗
7. 10.1021/acsnano.0c0285710.1021/acsnano.0c02857 ↗
8. Senanayake S. L. · Future Drug. Discovery · 2020 · 2 · 2
9. 10.1038/s41467-020-17189-210.1038/s41467-020-17189-2 ↗
10. 10.1038/s41598-020-70863-910.1038/s41598-020-70863-9 ↗
11. Zhou Y. · Lancet Global Health · 2020 · 2 · e667
12. 10.2174/15734091179567760210.2174/157340911795677602 ↗
13. 10.1016/B978-0-12-809633-8.20284-710.1016/B978-0-12-809633-8.20284-7 ↗
14. 10.1021/acsnano.6b0018110.1021/acsnano.6b00181 ↗
15. 10.1007/978-1-59745-177-210.1007/978-1-59745-177-2 ↗
16. Sanders J. M. · JAMA, J. Am. Med. Assoc. · 2020 · 18 · 1824
17. 10.1016/j.apsb.2020.02.00810.1016/j.apsb.2020.02.008 ↗
18. 10.1038/s41422-020-0282-010.1038/s41422-020-0282-0 ↗
19. 10.1038/nrd.2015.3710.1038/nrd.2015.37 ↗
20. 10.1016/j.cell.2020.02.05210.1016/j.cell.2020.02.052 ↗
21. 10.1038/s41421-020-0156-010.1038/s41421-020-0156-0 ↗
22. 10.1139/cjpp-2020-073410.1139/cjpp-2020-0734 ↗
23. 10.1371/journal.pone.001129510.1371/journal.pone.0011295 ↗
24. 10.1097/MJT.0b013e3180a6f9c210.1097/MJT.0b013e3180a6f9c2 ↗
25. Nestor M. S. · J. Clin. Aesthetic Dermatol. · 2016 · 3 · 25
26. 10.1128/AEM.02433-0910.1128/AEM.02433-09 ↗
27. 10.1016/j.cej.2011.07.05910.1016/j.cej.2011.07.059 ↗
28. 10.1021/nn400280c10.1021/nn400280c ↗
29. 10.1002/adfm.20150089110.1002/adfm.201500891 ↗
30. 10.1021/am502925j10.1021/am502925j ↗
31. 10.1002/smll.20190461910.1002/smll.201904619 ↗
32. 10.1002/adma.20150630610.1002/adma.201506306 ↗
33. 10.1039/C4CS00300D10.1039/C4CS00300D ↗
34. 10.1088/2053-1583/aac05c10.1088/2053-1583/aac05c ↗
35. 10.1007/978-1-4939-6840-4_2010.1007/978-1-4939-6840-4_20 ↗
36. 10.1002/advs.20190320010.1002/advs.201903200 ↗
37. 10.1002/smll.20190768610.1002/smll.201907686 ↗
38. 10.1371/journal.pone.016681610.1371/journal.pone.0166816 ↗
39. 10.1088/2053-1583/aac05c10.1088/2053-1583/aac05c ↗
40. 10.1016/j.chempr.2017.12.01710.1016/j.chempr.2017.12.017 ↗
41. 10.1021/acsnano.7b0773410.1021/acsnano.7b07734 ↗
42. 10.1039/C9NR02301A10.1039/C9NR02301A ↗
43. 10.1002/adtp.20200010910.1002/adtp.202000109 ↗
44. 10.1126/science.abb448910.1126/science.abb4489 ↗
45. 10.1016/j.nano.2016.08.01610.1016/j.nano.2016.08.016 ↗
46. 10.1177/204993611771359310.1177/2049936117713593 ↗
47. 10.1002/smll.20150085410.1002/smll.201500854 ↗
48. 10.3390/pharmaceutics1202017110.3390/pharmaceutics12020171 ↗
49. 10.1016/B978-0-323-52733-0.00014-810.1016/B978-0-323-52733-0.00014-8 ↗
50. 10.7150/thno.3986310.7150/thno.39863 ↗
51. 10.1021/acs.jpcc.8b0761610.1021/acs.jpcc.8b07616 ↗
52. Kunjiappan S. · Adv. Anticancer Agents Med. Chem. · 2019 · 16 · 1966
53. 10.1098/rsfs.2018.006310.1098/rsfs.2018.0063 ↗
54. 10.1021/acsomega.8b0086610.1021/acsomega.8b00866 ↗
55. 10.1016/j.jmgm.2015.07.00710.1016/j.jmgm.2015.07.007 ↗
56. 10.1007/s11224-016-0904-910.1007/s11224-016-0904-9 ↗
57. 10.1021/acsami.6b0457110.1021/acsami.6b04571 ↗
58. 10.3390/bios901001810.3390/bios9010018 ↗
59. 10.1039/C8CP01886C10.1039/C8CP01886C ↗
60. 10.1021/jz401929h10.1021/jz401929h ↗
61. 10.1038/s41598-019-44378-x10.1038/s41598-019-44378-x ↗
62. 10.1002/adma.20160652310.1002/adma.201606523 ↗
63. 10.7150/thno.4006810.7150/thno.40068 ↗
64. 10.3389/fbioe.2019.0029510.3389/fbioe.2019.00295 ↗
65. 10.1039/C5CS00914F10.1039/C5CS00914F ↗
66. 10.1021/am405040z10.1021/am405040z ↗
67. 10.1021/acsami.5b0687610.1021/acsami.5b06876 ↗
68. 10.1021/acs.bioconjchem.7b0003010.1021/acs.bioconjchem.7b00030 ↗
69. 10.1039/C9NR05273A10.1039/C9NR05273A ↗
70. Tremiliosi G. C. · bioRxiv. · 2020
71. Pezzotti G. · bioRxiv. · 2020
72. 10.1021/acsbiomaterials.0c0109110.1021/acsbiomaterials.0c01091 ↗
73. 10.1016/j.bbrc.2020.09.01810.1016/j.bbrc.2020.09.018 ↗
74. 10.1021/acs.nanolett.0c0227810.1021/acs.nanolett.0c02278 ↗
75. 10.1080/07391102.2020.181778810.1080/07391102.2020.1817788 ↗
76. De Maio F. · medRxiv. · 2020
77. 10.1016/j.cell.2020.07.01210.1016/j.cell.2020.07.012 ↗
78. Ogawa J. · bioRxiv. · 2020
79. 10.1002/jcc.2638310.1002/jcc.26383 ↗
80. 10.1038/s41598-020-70827-z10.1038/s41598-020-70827-z ↗
81. 10.1038/s41586-020-2180-510.1038/s41586-020-2180-5 ↗
82. 10.1074/jbc.M31119120010.1074/jbc.M311191200 ↗
83. 10.1016/j.cell.2020.02.05810.1016/j.cell.2020.02.058 ↗
84. 10.1002/jcc.2008410.1002/jcc.20084 ↗
85. Biovia Discovery Studio https://www.discngine.com/discovery-studio(accessed: May2020).
86. 10.1002/jcc.2125610.1002/jcc.21256 ↗
87. Trott O. · J. Comput. Chem. · 2010 · 2 · 45510.1002/jcc.21334 ↗
88. 10.1002/adhm.20120024810.1002/adhm.201200248 ↗